The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in <i>BRAF</i> mutant colorectal cancer

Robbie Carson; Basak Celtikci; Philip Dunne; Patrick Johnston; Sandra Van Schaeybroeck

doi:10.1158/1535-7163.TARG-13-B64

The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in <i>BRAF</i> mutant colorectal cancer

Robbie Carson
, Basak Celtikci
, Philip Dunne
, Patrick Johnston
, Sandra Van Schaeybroeck

Division of Medical Biochemistry (Medicine)

Queens University Belfast

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Molecular Cancer Therapeutics
Volume	12
Issue number	11
DOIs	https://doi.org/10.1158/1535-7163.TARG-13-B64
Publication status	Published - Nov 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1535-7163.TARG-13-B64

Cite this

@article{74ecbf59481d4cd098b88a8c7041ea75,

title = "The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF mutant colorectal cancer",

author = "Robbie Carson and Basak Celtikci and Philip Dunne and Patrick Johnston and \{Van Schaeybroeck\}, Sandra",

year = "2013",

month = nov,

doi = "10.1158/1535-7163.TARG-13-B64",

language = "English",

volume = "12",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "11",

}

TY - JOUR

T1 - The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF mutant colorectal cancer

AU - Carson, Robbie

AU - Celtikci, Basak

AU - Dunne, Philip

AU - Johnston, Patrick

AU - Van Schaeybroeck, Sandra

PY - 2013/11

Y1 - 2013/11

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000209496800284&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1158/1535-7163.TARG-13-B64

DO - 10.1158/1535-7163.TARG-13-B64

M3 - Meeting Abstract

SN - 1535-7163

VL - 12

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 11

ER -

The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in <i>BRAF</i> mutant colorectal cancer

UN SDGs

Access to Document

Other files and links

Cite this